Abstract
Until fairly recently, the only way of discovering anything about the nature of postsynaptic receptors for neurotransmitters was the time-honored method of studying the structure-activity relationships of agonists and antagonists. This information was usually incidental to the main practical preoccupation of finding compounds that were pharmacologically more active and specific. The nature of the information obtainable about receptors by this method is, of course, limited. One may show, for example, that in a particular drug certain chemical groups are essential for activity. Depending on the nature of these groups, it is possible to hypothesize binding via ionic or hydrogen bonds and van der Waals or hydrophobic interactions. However, the nature of the receptor components through which these interactions occur is in most cases totally unknown. There is also the problem that unless one works with conformationally rigid moelcules the actual shape of the drug on interaction with the receptor is uncertain. In recent years, more direct attempts have been made to learn something of the chemical nature of various receptors by actual isolation of the macromolecules thought to comprise the receptor material. An extensive review of earlier work in this area using a variety of reversible and irreversible agonists and antagonists has been published (Ehrenpreis et al., 1969). More recent studies are dealt with elsewhere in this series (Hollenberg and Cuatrecasas, Chap. 5, this volume; Changeux, Chap. 7, Vol. 6; Snyder, Chap. 6, Vol. 5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adamson, D. W., Barrett, P. A., Billinghurst, J. W., Green, A. F., Jones, T.S. G.: 1951. Geometrical Isomers in a Series of Antihistamines, Nature 168: 204–205.
Ahlquist, R. P.: 1948. A study of adrenotropic receptors, Am. J. Physiol. 153: 586–600.
Ahlquist, R. P.: 1968. Agents which block adrenergic A-receptors, in: Annual Review of Pharamacology, Vol 8 ( H. W. Elliott, ed.), pp. 259–272, Annual Reviews, Inc., Palo Alto, Calif.
Ainsworth, C.: 1958. Substituted β-aminoethylindazoles, J. Am. Chem. Soc. 80: 965–967.
Aizenshtat, Z., Klein, E., Weiler-Feilchenfeld, H., Bergmann, E. D.: 1972. Conformational studies on xanthene, thioxanthene and acridan, Israel J. Chem. 10: 753–763.
Anden, N. E., Roos, B. E., Werdinius, B.: 1964. Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum, Life Sci. 3: 149–158.
Anden, N. E., Rubenson, A., Fuxe, K., Hokfelt, T.: 1967. Evidence for dopamine receptor stimulation by apomorphine, J. Pharm. Pharmacol. 19: 627–629.
Anden, N. E., Butcher, S. G., Corrodi, H., Fuxe, K., Ungerstedt, U.: 1970. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics, Eur. J. Pharmacol. 11: 303–314.
Ariens, E. J.: 1963. in: First International Pharmacological Meeting Stockholm 1961, Vol. 7, p. 247, Macmillan, New York.
Ariens, E. J.: 1967. The structure-activity relationships of A-adrenergic drugs and A-adrenergic blocking drugs, Ann. N.Y. Acad. Sci. 139: 606–631.
Ariens, E. J.: 1971. A general introduction to the field of drug design, in: Drug Design, Vol. 1 ( E. J. Ariens, ed.), pp. 1–270, Academic Press, New York.
Ariens, E. J., Simonis, A. M.: 1964. A molecular basis for drug action, J. Pharm. Pharmacol. 16: 137–157.
Aroney, M. J., Hoskins, G. M., Lefevre, R. J. W.: 1968. Molecular polarisability: The conformations as solutes of phenothiazine and of N-methyl and N-phenylphenothiazine, J. Chem. Soc. (B) 1968: 1206–1208.
Ash, A. S. F., Schild, H. O.: 1966. Receptors mediating some actions of histamine, Brit. J. Pharmacol. 27: 427–439.
Bachrach, W. H.: 1958. Anticholinergic drugs: Survey of the literature and some experimental observations, Am. J. Digest. Dis. 3: 743–799.
Baker, R. W., Chothia, C. H., Pauling, P., Petcher, T. J.: 1971. Structure and activity of muscarinic stimulants, Nature 230: 439–445.
Banister, J., Whittaker, V. P.: 1951. Pharmacological activity of the carbon analogue of acetylcholine, Nature 167: 605–606.
Barger, G., Dale, H. H.: 1910. Chemical structure and sympathomimetic action of amines, J. Physiol. 41: 19–59.
Barlow, R. B.: 1964. Introduction to Chemical Pharamacology, 2nd ed., pp. 344–377, Wiley, New York.
Barlow, R. B., Kahn, I.: 1959a. Actions of some analogues of tryptamine on the isolated rat uterus and on the isolated rat fundus strip preparations, Brit. J. Pharmacol. 14: 99–107.
Barlow, R. B., Kahn, I.: 1959b. Actions of some analogues of 5-hydroxytryptamine on the isolated rat uterus and the rat fundus strip preparations, Brit. J. Pharmacol. 14: 265–272.
Barlow, R. B., Scott, K. A., Stephenson, R. P.: 1963. An attempt to study the effects of chemical structure on the affinity and efficacy of compounds related to acetylcholine, Brit. J. Pharmacol. 21: 509–522.
Barrett, A. M.: 1972. Design of α-blocking drugs, in: Drug Design, Vol. III. ( E. J. Ariens, ed.), pp. 205–228, Academic Press, New York.
Beckett, A. H., Harper, N. J., Clitherow, J. W., Lesser, E.: 1961. Muscarinic receptors, Nature 189: 671–673.
Beers, W. H., Reich, E.: 1970. Structure and activity of acetylcholine, Nature 228: 917–922.
Bell, C., Lang, W. J.: 1973. Neural dopaminergic vasodilator control in the kidney, Nature 246: 27–29.
Belleau, B.: 1965. In: Isotopes in Pharmacology (L. Roth, ed.), p. 469, University of Chicago Press, Chicago.
Belleau, B.: 1967. Stereochemistry of adrenergic receptors: Newer concepts on the molecular mechanism of action of catecholamines and antiadrenergic drugs at the receptor level, Ann. N.Y. Acad. Sci. 139: 580–605.
Bergin, R., Carlstrom, D.: 1968. The crystal structure of dopamine hydrochloride, Acta Crystallog. B24: 1506–1510.
Berridge, M. J.: 1972. The mode of action of 5-hydroxytryptamine, J. Exp. Biol. 56: 311–321.
Berridge, M. J., Patel, N. E.: 1968. Insect salivary glands: Stimulation of fluid secretion by 5-hydroxytryptamine and adenosine 3’,5’-monophosphate, Science 162: 462–463.
Bertaccini, G., Zamboni, P.: 1961. The relative potency of 5-hydroxytryptamine-like substances, Arch. Int. Pharmacodyn. 133: 138–156.
Beveridge, D. L., Radna, R. J.: 1971. A quantum theoretical study of the molecular electronic structure of acetylcholine, J. Am. Chem. Soc. 93: 3759–3764.
Biscoe, T. J., Curtis, D. R., Ryall, R. W.: 1966. An investigation of catecholamine receptors of spinal interneurones, Int. J. Neuropharmacol. 5: 429–434.
Black, J. M., Duncan, W. A. M., Shanks, R. G.: 1965. Comparison of some properties of pronethalol and propranolol, Brit. J. Pharmacol. 25: 577–591.
Black, J. W., Duncan, W. A. M., Durant, C. J., Ganellin, C. R., Parsons, E. M.: 1972. Definition and antagonism of histamine H2-receptors, Nature 236: 385–390.
Blinks, J. R.: 1967. Evaluation of the cardiac effects of several α-adrenergic blocking agents, Ann. N.Y. Acad. Sci. 139: 673–685.
Bloom, B. M., Goldman, I. M.: 1966. The nature of catecholamine-adenine mononucleotide interactions in adrenergic mechanisms, in: Advances in Drug Research, Vol. 3 ( N. J. Harper, A. B. Simmonds, eds.), pp. 121–169, Academic Press, London.
Bloom, F. E., Costa, E., Salmoiraghi, G. C.: 1964. Analysis of individual rabbit olfactory bulb neuron responses to the microelectrophoresis of acetylcholine, norepinephrine and serotonin synergists and antagonists, J. Pharmacol. Exp. Ther. 146: 16–23.
Boakes, R. J., Bradley, P. B., Brookes, N., Candy, J. M., Wolstencroft, J. H.: 1971. Actions of noradrenaline, other sympathomimetic amines and antagonists on neurones in the brain stem of the cat, Brit. J. Pharmacol. 41: 462–479.
Born, G. V. R.: 1971. In: Effects of Drugs on Cellular Control Mechanisms (B. R. Rabin, R. B. Freedman, eds.), pp. 237–257, Macmillan, London.
Bovet, D.: 1950. Introduction to antihistamine agents and antergan derivatives, Ann. N.Y. Acad. Sci. 50: 1089–1126.
Bovet, D., Bovet-Nitti, F.: 1948. In: Medicaments du Systeme Nerveux Vegetatif, pp. 222–237, Karger, Basel.
Bovet, D., Bovet-Nitti, F., Marini-Bettolo, G. B.: (eds.), 1959. Curare and Curare-like Agents, Elsevier, Amsterdam.
Brotzu, G.: 1970. Inhibition by chlorpromazine of the effects of dopamine on the dog kidney, J. Pharm. Pharmacol. 22: 664–667.
Brown, J. H., Makman, M. H.: 1972. Stimulation by dopamine of adenylate cyclase in retinal homogenates and of adenosine 3’,5’-cyclic monphosphate formation in intact retina, Proc. Natl. Acad. Sci. 69: 539–543.
Brown, J. H., Makman, M. H.: 1973. Influence of neuroleptic drugs and apomorphine on dopamine-sensitive adenylate cyclase of retina, J. Neurochem. 21: 477–479.
Burgen, A. S. V.: 1965. The role of ionic interaction at the muscarinic receptor, Brit. J. Pharmacol. 25: 4–17.
Burgen, A, S. V., Hiley, C. R., Young, J. M.: 1974a. The binding of 3H- propylbenzilylcholine mustard by longitudinal muscle strips from guinea-pig small intestine, Brit. J. Pharmacol. 50: 145–151.
Burgen, A. S. V., Hiley, C. R., Young, J. M.: 1974b. The properties of muscarinic receptors in mammalian cerebral cortex, Brit. J. Pharmacol., 51: 279–285.
Burger, A., Bernabe, M., Collins, P. W.: 1970. (4-Imidazolyl) Cyclopropylamine, J. Med. Chem. 13: 33–35.
Burks, T. F., Long, J. P., Darko, L. L., Cannon, J. G.: 1965. Evaluation of n-methoxy substitution in cholinergic agents, Fed. Proc. 24: 611.
Burns, J. J., Colville, K. I., Lindsay, L. A., Salvador, R. A.: 1964. Blockade of some metabolic effects of catecholamines by N-isopropyl methoxamine (B. W. 61–43), J. Pharmacol. Exp. Ther. 144: 163–171.
Burns, T. W., Langley, P. E., Robison, G. A.: 1971. Adrenergic receptors and cyclic AMP: Regulation of human adipose tissue lipolysis, Ann. N.Y. Acad. Sci. 185: 115–128.
Cameron, W. M., Tainter, M. L.: 1936. Comparative actions of sympathomimetic compounds: Bronchiodilator actions in bronchial spasms induced by histamine, J. Pharmacol. Exp. Ther. 57: 152–169.
Campaigne, E., Knapp, D. R., Neiss, E. S., Bosin, T. R.: 1970. Biologically active benzothiophene derivatives, in: Advances in Drug Research, Vol. 5 ( N. J. Harper, A. B. Simmonds, eds.), pp. 1–54, Academic Press, London.
Canepa, F. G., Pauling, P. J., Sorum, H.: 1966. Structure of acetylcholine and other substrates of cholinergic systems, Nature 210: 907–909.
Cannon, J. G., Long, J. P.: 1967. Postganglionic parasympathetic depressants, in: Drugs Affecting the Peripheral Nervous System ( A. Burger, ed.), pp. 133–148, Dekker, New York.
Carlsson, A., Lindqvist, M.: 1963. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain, Acta Pharmacol. Toxicol. 20: 140–144.
Carlsson, A., Fuxe, K., Hamberger, B., Lindqvist, M.: 1966. Biochemical and histochem- ical studies of the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons, Acta Physiol. Scand. 67: 481–497.
Carlstrom, D., Bergin, R.: 1967. The crystal structure of noradrenaline hydrochloride, Acta Crystallog. 23: 313–319.
Carlstrom, D., Bergin, R., Falkenberg, G.: 1973. Molecular characteristics of biogenic monoamines and their analogs, Quart. Rev. Biophys. 6: 257–310.
Carr, L. A., Moore, K. E.: 1970. Effects of amphetamine on the contents of norepinephrine and its metabolites in the effluent of perfused cerebral ventricles of the cat, Biochem. Pharmacol. 19: 2361–2374.
Casy, A. F., Ison, R. R., Ham, N. S.: 1970. The conformation of histamine in solution: Nuclear magnetic resonance study, Chem. Commun. 1970: 1343–1344.
Chang, H. C., Gaddum, J. H.: 1933. Choline esters in tissue extracts, J. Physiol. 79: 255–285.
Chothia, C.: 1970a. Interaction of acetylcholine with different cholinergic nerve receptors, Nature 225: 36–38.
Chothia, C.: 1970b. Structure-activity relationships of some muscarinic agonists: A reply to Shefter and Triggle, Nature 227: 1355–1356.
Chothia, C., Pauling, I.: 1968. Conformations of acetylcholine, Nature 219: 1156–1157.
Chothia, C., Pauling, P.: 1970. The conformation of cholinergic molecules at nicotinic nerve receptors, Proc. Natl. Acad. Sci. 65: 477–482.
Cole, B., Robison, G. A., Hartmann, R. C.: 1971. Studies on the Role of Cyclic AMP in Platelet Function, Ann. N.Y. Acad. Sci. 185: 477–487.
Colhoun, E. H.: 1963. Synthesis of 5-hydroxytryptamine in the American cockroach, Experientia 19: 9–10.
Corrodi, H., Persson, H., Carlsson, A., Roberts, J.: 1963. A new series of substances which block the adrenergic a-receptors, J. Med. Chem. 6: 751–755.
Coyle, J. T., Snyder, S. H.: 1969. Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action, Science 166: 899–901.
Cuello, A. C., Horn, A. S., Mackay, A. V. P., Iversen, L. L.: 1973. Catecholamines in the median eminence: New evidence for a major noradrenergic input, Nature 243: 465–467.
Culvenor, C. C. J., Ham, N. S.: 1966. The proton magnetic resonance spectrum and conformation of acetylcholine, Chem. Commun. 1966: 537–539.
Cushley, R. J., Mautner, H. G.: 1970. N.M.R. studies on the conformation of acetylcholine isologues, Tetrahedron 26: 2151–2159.
Cuthbert, A. W., Young, J. M.: 1973. The number of muscarinic receptors in chick amnion muscle, Brit. J. Pharmacol. 49: 498–505.
Dale, H. H.: 1906. On some physiological actions of ergot, J. Physiol. 34: 163–206.
Dale, H. H.: 1953. Adventures in Physiology, Pergamon Press, London.
Dalgliesh, C. E., Toh, C. C., Work, T. S.: 1953. Fractionation of the smooth muscle stimulants present in extracts of gastro-intestinal tract: Identification of 5-hydroxytryptamine and its distinction from substance P, J. Physiol. 120: 298–310.
Daprada, M., Pletscher, A.: 1966. Acceleration of cerebral dopamine turnover by chlorpromazine, Experientia 22: 465–466.
Dollery, C. T., Paterson, J. W., Conolly, M. E.: 1969. Clinical pharmacology of beta receptor blocking drugs, Clin. Pharmacol. Ther. 10: 765–799.
Dorignac-Calas, M. R., Marsau, P.: 1972. Structure cristalline du chlorhydrate de chloro-3 (dimethylamino-3’propyl)-10-phenothiazine, Comp. Rend. Acad. Sei. Paris 274: 1806–1809.
Dunitz, J. D., Eser, H., Strickler, P.: 1964. Die Konfiguration des physiologisch Wirksamen 2-Chloro-9-(w-dimethylaminopropyliden)-thioxanthens, Helv. Chim. Acta 47: 1897–1902.
Ehrenpreis, S., Fleisch, J. H., Mittag, T. W.: 1969. Approaches to the molecular nature of pharmacological receptors, Pharmacol. Rev. 21: 131–181.
Ellenbroek, B. W. J., van Rossum, J. N.: 1960. Absolute configuration and parasympathomimetic activity—Chemistry and pharmacology of acetyl-γ-methyl choline, Arch. Int. Pharmacodyn. 125: 216–220.
Erlenmeyer, H., Lobeck, H.: 1937. Darstellung und Eigenschaften des Acetyl-β-cholin, Helv. Chim. Acta 20: 142–150.
Ernst, A. M.: 1967. Mode of action of apomorphine and D-amphetamine for gnawing compulsion in rats, Psychopharmacologia 10: 316–323.
Erspamer, V.: 1940. Pharmakologische Studien über Enteramin. I, Naunyn-Schmiedberg’s Arch. Exp. Pathol. Pharmakol. 196: 343–365.
Erspamer, V.: 1954. II sistema cellulare enterocromaffine e L’enteramina (5-idrossitriptamina), Rend. Sei. Farm. 1: 1–193.
Erspamer, V.: 1966. Bioassay of indoleaklyamines, in: 5-Hydroxytryptamine and Related Indolealkylamines (O. Elchler, A. Farah, eds.), pp. 132–181, Vol. 19 of Handbook of Experimental Pharmacology, Springer, Berlin.
Eugster, C. H.: 1959. Synthese and pharmakologische Eigenschaften des Desmethylmus- carones und der stereoisomeren Desmethylmuscarine Die Basen starken der isomeren Normuscarine, Helv. Chim. Acta 42: 1177–1189.
Everett, A. J., Laue, L. A., Wilkinson, S.: 1970. Revision of the structures of (+)-tubocurarine chloride and (+)-chondrocurine, Chem. Commun. 1970: 1020–1021.
Fellman, J. H., Fujita, T. S., Belber, C. J.: 1962. β-Dihydro-δ-Hydroxytryptamine, Biochem. Pharmacol. 11: 557–561.
Fewtrell, C. M. S., Rang, H. P.: 1973. Labelling cholinergic receptors in smooth muscle, in: Drug Receptors ( H. P. Rang, ed.), pp. 211–224, Macmillan, London.
Freyhan, F. A.: 1961. In: Extrapyramidal System and Neuroleptics (J. M. Bordeleau, ed.), pp. 483–486, Editions Psychiatriques, Montreal.
Friedman, H. L.: 1967. Postganglionic parasympathetic stimulants, in: Drugs Affecting the Peripheral Nervous System, ( A. Burger, ed.), pp. 79–131, Dekker, New York.
Furchgott, R. F.: 1972. The classification of adrenoceptors (adrenergic receptors): An evaluation from the standpoint of receptor theory, in: Catecholamines, (H. Blaschko, E. Muscholl, eds.), pp. 283–335, Vol. 33 of Handbook of Experimental Pharmacology, Springer, Berlin.
Fuxe, K.: 1965. Evidence for the existence of monoamine neurons in the central nervous system. IV. Distribution of monamine nerve terminals in the central nervous system, Acta Physiol. Scand. 64:37–85 (Suppl. 247 ).
Gaddum, J. H., Hameed, K. A.: 1954. Drugs which antagonize δ-hydroxytryptamine, Brit. J. Pharmacol. 9: 240–248.
Gaddum, J. H., Paasonen, M. K.: 1955. The use of some molluscan hearts for the estimation of 5-hydroxytryptamine, Brit. J. Pharmacol. 10: 474–483.
Gaddum, J. H., Picarelli, Z.: 1957. Two kinds of tryptamine receptors, Brit. J. Pharmacol. 12: 323–328.
Garattini, S., Valzelli, L.: 1965. Serotonin, Elsevier, Amsterdam.
Gearien, J. E.: 1970. Cholinergics and anticholinesterases, in: Medicinal Chemistry, Part II, 3rd ed. ( A. Burger, ed.), pp. 1296–1313, Wiley-Interscience, New York.
Geiger, W. B., Alpers, H.: 1964. Properties of an acetylated derivative of trimethylamine oxide, Arch. Int. Pharmacodyn. 148: 352–358.
Giesecke, J.: 1973. The crystal and molecular structure of apomorphine hydrochloride hydrate, Acta Crystallog. B29: 1785–1791.
Gill, E. W., Rang, H. P.: 1966. An alkylating derivative of benzilycholine with specificand long-lasting parasympatholytic activity, Mol. Pharmacol. 2: 284–297.
Glowinski, J.: 1970. Effects of amphetamine on various aspects of catecholamine metabolism in the central nervous system of the rat, in: Amphetamines and Related Compounds ( E. Costa, S. Garattini, eds.), pp. 301–316, Raven Press, New York.
Goldberg, L. I., Sonneville, P. F., Mcnay, J. L.: 1968. An investigation of the structural requirements for dopamine-like renal vasodilation: Phenylethylamines and apomorphine, J. Pharmacol. Exp. Ther. 163: 188–197.
Goodman, L. S., Gilman, A.: 1970. The Pharmacological Basis of Therapeutics, 4th ed., Macmillan, New York.
Gordon, M.: 1967. Phenothiazines, in: Psychopharmacological Agents, Vol. 11, ( M. Gordon, ed.), pp. 1–198, Academic Press, New York.
Green, A. L.: 1967. Activity correlations and the mode of action of aminoalkylphenothiazine tranquillizers, J. Pharm. Pharmacol. 19: 207–208.
Greenberg, M. J.: 1960. Structure-activity relationship of tryptamine analogues on the heart of Venus mercenaria, Brit. J. Pharmacol. 15: 375–388.
Gunn, J. A., Gurd, M. R.: 1940. The action of some amines related to adrenaline: Cyclohexylalkylamines, J. Physiol. 97: 453–470.
Gyermek, L.: 1961. β-Hydroxy tryptamine antagonists, Pharmacol. Rev. 13: 399–439.
Gyermek, L.: 1966. Drugs which antagonize 5-hydroxytryptamine and related indolealkylamines, in: δ-Hydroxytryptamine and Related Indolealkylamines (O. Eichler, A. Farah, eds.), pp. 471–528, Vol. 19 of Handbook of Experimental Pharmacology, Springer, Berlin.
Gyermek, L., Bindler, E.: 1962. Action of indole alkylamines and amidines on the inferior mesenteric ganglion of the cat, J. Pharmacol. Exp. Ther. 138: 159–164.
Gyermek, L., Nador, K.: 1957. The pharmacology of tropane compounds in relation to their steric structure, J. Pharm. Pharmacol. 9: 209–229.
Gyermek, L., Unna, K. R.: 1958. Relation of structure of synthetic muscarines and muscarones to their pharmacological action, Proc. Soc. Exp. Biol. Med. 98: 882–885.
Harms, A. F., Nauta, W. T.: 1960. The effects of alkyl substitution on drugs. 1. Substituted dimethylaminoethyl benzhydryl ethers, J. Med. Pharm. Chem. 2: 57–77.
Harrison, D. C.: 1971. Circulatory Effects and Clinical Uses of Beta-Adrenergic Blocking Drugs, Excerpta Medica, Amsterdam and London.
Haylett, D. G., Jenkinson, D. H.: 1972. Effects of noradrenaline on potassium efflux, membrane potential and electrolyte levels in tissue slices prepared from guinea-pig liver, J. Physiol. 225: 721–750.
Hebb, C. O., Krnjevic, K.: 1962. Neurochemistry (K. A. C. Elliot, I. H., Page, J. H. Quastel, eds.), pp. 452–521, Thomas, Springfield, 111.
Hiley, C. R., Burgen, A. S. V.: 1974. The distribution of muscarinic receptor sites in the nervous system of the dog, J. Neurochem. 22: 159–162.
Hiley, C. R., Young, J. M., Burgen, A. S. V.: 1972. Labelling of cholinergic receptors in subcellular fractions from rat cerebral cortex, Biochem. J. 127: 86 P.
Holton, P., Ing, H. R.: 1949. Specificity of the trimethylammonium group in acetylcholine, Brit. J. Pharmacol. 4: 190–196.
Horn, A. S., Snyder, S. H.: 1971. Chlorpromazine and dopamine: Conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs, Proc. Natl. Acad. Sci. 68: 2325–2328.
Horn, A. S., Cuello, A. C., Miller, R. J.: 1974. Dopamine in the mesolimbic system of the rat brain: Endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity, J. Neurochem. 22: 265–270.
Hornykiewicz, O.: 1966. Dopamine and brain function, Pharmacol. Rev. 18: 925–964.
Howe, R.: 1963. Structure-activity relationships of some α-adrenergic blocking agents, Biochem. Pharmacol. Suppl. 12: 85–86.
Hunt, C. C., Kuffler, S. W.: 1950. Pharmacology of the neuromuscular junction, Pharmacol. Rev. 2: 96–120.
Hunt, R., Renshaw, R. R.: 1925. On some effects of arsonium, stibonium, phosphonium and sulfonium compounds on the autonomic nervous system, J. Pharmacol. Exp. Ther. 25: 315–355.
Hunt, R., Renshaw, R. R.: 1932. Thio and thiomethyl ammonium compounds, J. Pharmacol. Exp. Ther. 44: 151–169.
Hunt, R., Renshaw, R. R.: 1933. Effects of some quaternary ammonium and analogous compounds on the autonomic nervous system, J. Pharmacol. Exp. Ther. 48: 51–66.
Hunt, R., Taveau, R. de M.: 1906. On the physiological action of certain cholin derivatives and new methods for determining cholin, Brit. Med. J. 2: 1788–1791.
Hunt, R., Taveau, R. de M.: 1909. On the relation between the toxicity and chemical constitution of a number of derivatives of choline and analogous compounds, J. Pharmacol. Exp. Ther. 1: 303–339.
Huttrer, C. P.: 1947. Chemistry of antihistamine substances, Enzymologia 12: 277–332.
Idson, B.: 1950. Antihistamine drugs, Chem. Rev. 47: 307–527.
Ing, H. R.: 1936. The curariform action of onium salts, Physiol. Rev. 16: 527–544.
Ing, H. R.: 1946. Synthetic substitutes for atropine, Brit. Med. Bull. 4: 91–95.
Ing, H. R.: 1949. The structure-action relationships of the choline group, Science 109: 264–266.
Ing, H. R.: 1956. Structure-action relationships of hypotensive drugs, in: Hypotensive Drugs ( M. Harrington, ed.), pp. 7–22, Pergamon Press, Oxford.
Ing, H. R., Kovdik, P., Tudor-Williams, D. P. H.: 1952. The structure-action relationships of the choline group, Brit. J. Pharmacol. 7: 103–116.
Ison, R. R., Partington, P., Roberts, G. C. K.: 1973. The conformation of catecholamines and related compounds in solution, Mol. Pharmacol. 9: 756–765.
Jacob, J., Marszak, I., Bardisa, L., Marszak-Fleury, A., Epsztein, R.: 1952. The relation of structure to activity in certain acetylcholine, ethylene and saturated derivatives of choline and acetylcholine. Arch. Int. Pharmacodyn. 91: 303–321.
Janssen, P. A. J.: 1965. The evolution of the butyrophenones, haloperidol and trifluperidol from meperidine like 4-phenylpiperidines, Int. Rev. Neurobiol. 8: 221–263.
Janssen, P. A. J.: 1967. Haloperidol and related butyrophenones, in: Psychopharmacological Agents ( M. Gordon, ed.), pp. 199–248, Academic Press, New York.
Janssen, P. A. J.: 1973. Structure-activity relationships (SAR) and drug design as illustrated with neuroleptic drugs, in: Structure-Activity Relationships ( C. J. Cavalitto, ed.), pp. 37–73, International Encyclopedia of Pharmacology and Therapeutics, Pergamon Press, Oxford.
Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L.: 1967. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? Part IV, Arzneimittel-Forsch. 17: 841–854.
Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., Dresse, A., Lenaerts, F. M., Pinchard, A., Schaper, W. K. A., van Nueten, J. M., Verbruggen, F. J.: 1968. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug, Arzneimittel-Forsch. 18: 261–279.
Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., Lenaerts, F. M., Verbrulggen, F. J., van Nueten, J. M., Marsboom, R. H. M., Herin, V. V., Schaper, W. K. A.: 1970. The pharmacology of fluspirilene (R6218), a potent, long acting and injectable neuroleptic drug, Arzneimittel-Forsch. 20: 1689–1698.
Jarrousse, M. J., Regnier, M. T.: 1951. Separation et activite physiologique des deux isomeres optiques du dimethylaminoethoxy-β-tolyphenylmethane, Ann. Pharm. Franc. 9: 321–325.
Jones, R. G.: 1966. Chemistry of histamine and analogs: Relationship between structure and pharmacological activity, in: Histamine and Anti-histamines, Part 1 (O. Eichler, A. Farah, eds.), pp. 1–43, Vol. 18 of Handbook of Experimental Pharmacology, Springer, Berlin.
Kamenar, B., Prout, K., Ganellin, C. R.: 1973. Crystal and molecular structure of the histamine H2-receptor antagonist N-(4-imidazol-4-ylbutyl)-N-methyl thiourea (burimamide), J. Chem. Soc. (Perkin Trans.) 11: 1734–1739.
Katz, R., Heller, S. R., Jacobson, A. E.: 1973. A molecular orbital study of norepinephrine and 3,4-dihydroxyphenethylamine: A re-evolution of structure-activity relationships in norepinephrine, Mol. Pharmacol. 9: 486–494.
Kebabian, J. W., Petzold, G. L., Greengard, P.: 1972. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain and its similarity to the “dopamine receptor,” Proc. Natl. Acad. Sci. 69: 2145–2149.
Kerkut, G. A.: 1973. Catecholamines in invertebrates, Brit. Med. Bull. 29: 100–104.
Kerkut, G. A., Walker, R. J.: 1961. The effects of drugs on the neurones of the snail, Helix aspersa, Comp. Biochem. Physiol. 3: 143–160.
Kier, L. B.: 1967. Molecular orbital calculation of preferred conformations of acetylcholine, muscarine and muscarone, Mol. Pharmacol. 3: 487–494.
Kier, L. B.: 1968a. Preferred conformation of serotonin and a postulate on the nature of its receptor from molecular orbital calculations, J. Pharm. Sci. 57: 1188–1191.
Kier, L. B.: 1968b. Molecular orbital calculations of the preferred conformations of histamine and a theory on its dual activity, J. Med. Chem. 11: 441–445.
Klein, D. F., Davis, J. M.: 1969. Diagnosis and Treatment of Psychiatric Disorders, Williams and Wilkins, Baltimore.
Koch, M. H. J.: 1973. 4-(4-Chloro-a, a, a-trifluoro-m-tolyl)-l-[4,4-bis-(-fluorophenyl)butyl]-4- piperidinol (penfluridol), Acta Crystallog. B29: 1538–1540.
Koch, M. H. J., Germain, G.: 1972. The crystal and molecular structure of 4’-fluoro-4-(1- [4-hydroxy-4-(4’-fluoro)-phenylpiperidinol])butyrophenone and its hydrochloride, Acta Crystallog. B28: 121–125.
Korolkovas, A.: 1970. In: Essentials of Molecular Pharmacology: Background for Drug Design, Wiley, New York.
Koshland, D. E.: 1958. Application of a theory of enzyme specificity to protein synthesis, Proc. Natl. Acad. Sci. 44: 98–104.
Kvam, D. C., Riggilo, D. A., Lish, P. M.: 1965. Effect of some new α-adrenergic blocking agents on certain metabolic responses to catecholamines, J. Pharmacol. Exp. Ther. 149: 183–192.
Lal, S., Sourkes, T. L.: 1972. Effects of various chlorpromazine metabolites on amphetamine induced stereotyped behaviour in the rat, Eur. J. Pharmacol. 17: 283–286.
Lands, A. M.: 1951. An investigation of the molecular configurations favorable for stimulation or blockade of the acetylcholine-sensitive receptors of visceral organs, J. Pharmacol. Exp. Ther. 102: 219–236.
Lands, A.M.: 1952a. The cardiovascular actions of l-β-aminophenyl)-2-aminoethanol and related compounds, J. Pharmacol. Exp. Ther. 104: 474–477.
Lands, A. M.: 1952b. The effect on blood pressure and toxicity of l-β-fluorophenyl)-2- aminoethanol and related compounds, J. Pharmacol. Exp. Ther. 106: 440–443.
Lands, A. M., Brown, T. G.: 1967. Sympathomimetic (adrenergic) stimulants, in: Drugs Affecting the Peripheral Nervous System ( A. Burger, ed.), pp. 399–472, Dekker, New York.
Lands, A. M., Cavallito, C. J.: 1954. An evaluation of the factors favorable for acetylcholine like stimulation by employing a series of quaternary ammonium alkyl sulfide and sulfoxide compounds, J. Pharmacol. Exp. Ther. 110: 369–384.
Lands, A. M., Grant, J. I.: 1952. The vasopressor action and toxicity of cyclohexylethylamine derivatives, J. Pharmacol. Exp. Ther. 106: 341–345.
Lands, A. M., Luduena, F. P.: 1956. The cholinolytic action of substituted dialkylaminoalkanes and dialkylaminoalkanols, J. Pharmacol. Exp. Ther. 116: 177–190.
Lands, A. M., Tainter, M. I.: 1953. The effect of changes in molecular configuration on inhibitory sympathomimetic action, Arch. Exp. Pathol. Pharmakol. 219: 76–96.
Lands, A. M., Nash, V. L., Mccarthy, H. M., Granger, H. R., Dertinger, B. L.: 1947a. The pharmacology of N-alkyl homologues of epinephrine, J. Pharmacol. Exp. Ther. 90: 110–119.
Lands, A. M., Nash, V. L., Granger, H. R., Dertinger, B. L.: 1947b. The pharmacologic activity of N-methyl-ß-cyclohexyl-isopropylamine HC1, J. Pharmacol. Exp. Ther. 89: 383–385.
Lands, A. M., Nash, V. L., Dertinger, B. L., Granger, H. R., Mccarthy, H. M.: 1948. The pharmacology of compounds structurally related to hydroxytryptamine, J. Pharmacol. Exp. Ther. 92: 369–380.
Langer, S. Z., Rubio, M. C.: 1973. Effects of the noradrenaline metabolites on the adrenergic receptors, Naunyn Schmiedebergs Arch. Pharmakol. 276: 71–88.
Larsen, A. A., Gould, W. A., Roth, H. R., Comer, W. T., Uloth, R. H., Dungan, K. W., Lish, P. M.: 1967. Sulfonanilides. II. Analogs of Catecholamines, J. Med. chem. 10: 462–472.
Laverty, R., Sharman, D. H.: 1965. Modification by drugs of the metabolism of 3,4-dihydroxy phenylethylamine, noradrenaline and 5-hydroxytryptamine in the brain, Brit. J. Pharmacol. 24: 759–772.
Lehmann, G., Randall, L. O.: 1948. Pharmacological properties of sympathomimetic diamines, J. Pharmacol. Exp. Ther. 93: 115–125.
Leonard, F., Huttrer, C. P.: 1956. Histamine Antagonists, Chemical Biological Coordination Center, National Research Council, Washington, D.C.
Lewis, J. J., Muir, T. C.: 1967. Drugs acting at nerve-skeletal muscle junctions, in: Drugs Affecting the Peripheral Nervous System (A. Burger, ed.), pp. 327–364, Dekker, New York.
Liquori, A. M., Damiani, A., Elefante, G.: 1968a. Calculated minimum energy conformations of muscarine, J. Mol. Biol. 33: 439–444.
Liqouri, A. M., Damiani, A., Decoen, J. L.: 1968b. Calculated minimum energy conformations of acetylcholine, J. Mol. Biol. 33: 445–450.
Loew, E. R.: 1947. Pharmacology of antihistamine compounds, Physiol. Rev. 27: 542–573.
Loewi, O.: 1921. Uber humor ale Ubertragbarkeit der Herznervenwirkung. I. Milleilung, Pfluegers Arch. Ges. Physiol. 189: 239–242.
Marsh, D. F., Howard, A., Herring, D. A.: 1951. The comparative pharmacology of the isomeric nitrogen methyl substituted heptylamines, J. Pharmacol. Exp. Ther. 103: 325–329.
Marszak, I., Olomucki, M., Epsztein, R., Jacob, J.: 1954. Unsaturated amines. IX. Synthesis and parasympathomimetic properties of ethylenic quaternary ammonium salts, Comp. Rend. Acad. Sci. Paris 238: 166–168.
Matthysse, S.: 1973. Antipsychotic drug actions: A clue to the neuropathology of schizophrenia? Fed. Proc. 32: 200–205.
Mayer, S. E., Stull, J. T.: 1971. Cyclic AMP in Skeletal Muscle, Ann. N.Y. Acad. Sci. 185: 433–448.
Mcdowell, J. J. H.: 1969. The crystal and molecular structure of chlorpromazine, Acta Crystallog. B25: 2175–2181.
Mcgeer, E. G., Mcgeer, P. L., Mclennan, H.: 1961. The inhibitory action of δ-hydroxytryptamine, gamma-aminobutyric acid (GABA) and some other compounds towards the crayfish stretch receptor neuron, J. Neurochem. 8: 36–49.
Mcisaac, W. M., Page, I. H.: 1958. New metabolites of serotonin in carcinoid urine, Science 128: 537.
Mcnay, J. L., Mcdonald, R. H., Goldberg, L. I.: 1965. Direct renal vasodilation produced by dopamine in the dog, Circ. Res. 16: 510–517.
Melville, K. I.: 1973. Antihistamine drugs, in: Histamine and Antihistamines ( M. Schachter, ed.), pp. 127–171, International Encyclopedia of Pharmacology and Therapeutics, Pergamon Press, Oxford.
Miller, R. J., Hiley, C. R.: 1974. Relation of anti-muscarinic properties of neuroleptics to drug induced parkinsonism, Nature 248: 596–597.
Miller, R. J., Iversen, L. L.: 1974. Effect of psychoactive drugs on dopamine (3,4- dihydroxyphenethylamine)-sensitive adenylate cyclase activity in corpus striatum of rat brain, Biochem. Soc. Trans. 1: 90–93.
Moe, G. K., Freyburger, W. A.: 1950. Ganglionic Blocking Agents, Pharmacol. Rev. 2: 61–95.
Moller-Nielsen, I., Hougs, W., Lassen, N., Holm, T., Petersen, P. V.: 1962. Central Depressant Activity of Some Thiaxanthene Derivatives, Acta Pharmacol. Toxicol. 19: 87–100.
Moller-Nielsen, I., Pedersen, V., Nymark, M., Franck, K. F., Boeck, V., Fjallan, B., Christensen, A. V.: 1973. The Comparative Pharmacology of Flupenthixol and Some Reference Neuroleptics, Acta Pharmacol. Toxicol. 33: 353–362.
Nachod, F. C., Lands, A. M.: 1953. Relationship between chemical structure and biological activity of compounds with atropine-like activity, Trans. N.Y. Acad. Sci. 16: 2–13.
Nauta, W. T., Rekker, R. F., Harms, A. F.: 1968. Diarylcarbinolethers: Structure-activity relationships. A physico-chemical approach, in: Proceedings of the Third International Pharmacology Meeting, Vol. 7, pp. 305–325, Pergamon Press, New York.
Nogradi, M., Ollis, W. D., Sutherland, I. D.: 1970. The conformational inversion of 2,3:6,7-dibenzo-derivatives of cycloheptatriene, tropone, heptafulvene, oxepin, thiepin and azepin, Chem. Commun. 1970: 158–160.
Nyback, H.: 1971. Regional disappearance of catecholamines formed from 14C-tyrosine in rat brain: Effect of synthesis inhibitors and of chlorpromazine, Acta Pharmacol. Toxicol. 30: 372–384.
Nyback, H., Sedvall, G.: 1968. Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain, J. Pharmacol. Exp. Ther. 162: 294–301.
Nyback, H., Sedvall, G.: 1972. Effect of chlorpromazine and some of its metabolites on synthesis and turnover of catecholamines formed from I4C-tyrosine in mouse brain, Psychopharmacologia 26: 155–160.
Osborne, M., Detar, R., Gabel, L.: 1962. Comparison between the autonomic pharmacology of 5-hydroxytryptamine and 5-acetyltryptamine (5-AT), Fed. Proc. 21: 324.
Paton, W. D. M., Zaimis, E. J.: 1952. The methonium compounds, Pharmacol. Rev. 4: 219–253.
Pauling, P., Petcher, T. J.: 1973. Neuromuscular blocking agents: Structures and activity, Chem. Biol. Interact. 6: 351–365.
Pederson, L., Hoskins, R. E., Cable, H.: 1971. The preferred conformation of noradrenaline, J. Pharm. Pharmacol. 23: 216–218.
Periti, P. F.: 1970. On active conformation of histamine and analogues, Pharmacol. Res. Commun. 2: 309–318.
Petersen, P. V., Moller-Nielsen, I.: 1964. Thioxanthene derivatives, in: Psychopharmacological Agents, Vol. 1 ( M. Gordon, ed.), pp. 301–324, Academic Press, New York.
Phillis, J. W., Tebecis, A. K.: 1967. The responses of thalamic neurones to iontophoretically applied monoamines, J. Physiol. 192: 715–745.
Post, M. L., Kennard, O., Horn, A. S.: 1974. 2-Chloro-9-(w-dimethyl- aminopropylidene)thioxanthene, Acta Crystallog B30: 1644–1646.
Powell, C. E., Slater, I. H.: 1958. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol, J. Pharmacol. Exp. Ther. 122: 480–488.
Pratesi, P., La Manna, A., Campiglio, A., Ghislandi, V.: 1958. The configuration of adrenaline and of its β-hydroxyphenyl analogue, J. Chem. Soc. 1958: 2069–2074.
Pratesi, P., La Manna, A., Campiglio, A., Ghislandi, V.: 1959. The configuration of Noradrenaline, J. Chem. Soc. 1959: 4062–4065.
Pullman, B., Courriere, P., Coubeils, J. L.: 1971. Quantum mechanical study of the conformational and electronic properties of acetylcholine and its agonists muscarine and nicotine, Mol. Pharmacol. 7: 397–405.
Pullman, B., Coubeils, J. L., Courriere, P., Gervois, J. P.: 1972. Quantum mechanical study of the conformation properties of phenethylamines of biochemical and medical interest, J. Med. Chem. 15: 17–23.
Randrup, A., Munkvad, I.: 1970. Biochemical anatomical and psychological investigations of stereotyped behavior induced by amphetamines, in: Amphetamines and Related Compounds ( E. Costa, S. Garattini, eds.), pp. 695–713, Raven Press, New York.
Randrup, A., Scheel-Kruger, J.: 1966. Diethyldithiocarbamate and amphetamine stereotype behaviour, J. Pharm. Pharmacol. 18: 752.
Randrup, A., Munkvad, I., Udsen, P.: 1963. Adrenergic mechanisms and amphetamine induced abnormal behaviour, Acta Pharmacol. Toxicol. 20: 145–157.
Reed, L. L., Schaefer, J. P.: 1973. The crystal and molecular structure of haloperidol, a potent psychotropic drug, Acta Crystallog. 829: 1886–1890.
Renshaw, R. R., Hopkins, C. T.: 1929. Phosphoric acid ester derivatives of choline: Basis for the psychological activity of -onium compounds, J. Am. Chem. Soc. 51: 953–964.
Renshaw, R. R., Hunt, R.: 1929. The pharmacological action of some homologues of betaine and choline esters, J. Pharmacol. Exp. Ther. 37: 309–337.
Renshaw, R. R., Dreisbach, P. F., Ziff, M., Green, D.: 1938. Thioesters of choline and O-methylcholine and their psychological activity: Onium compounds, J. Am. Chem. Soc. 60: 1765–1770.
Robison, G. A., Butcher, R. W., Sutherland, E. W.: 1967. Adenylcyclase as an adrenergic receptor, Ann. N.Y. Acad. Sci. 139: 703–723.
Robison, G. A., Butcher, R. W., Sutherland, E. W.: 1971. Cyclic AMP, p. 225, Academic Press, New York.
Rocha, E., Silva, M.: 1960. Influence of pH on the interaction of histamine with its receptors in the guinea pig ileum, Arch. Int. Pharmacodyn. 128: 355–374.
Saavedra, J. M., Brownstein, M., Axelrod, J.: 1973. A specific and sensitive enzymaticisotopic microassay for serotonin in tissues, J. Pharmacol. Exp. Ther. 186: 508–515.
Salle, J.: 1952. The pharmacology of fluroacetylcholine bromide, Arch. Int. Pharmacodyn. 91: 339–349.
Sastry, B. V. R., Pfeiffer, C. C., Lasslo, A.: 1960. Relation between chemical constitution and biological response of D(—), L(+) and DL-lactoylcholines and related compounds, J. Pharmacol. Exp. Ther. 130: 346–355.
Schaefer, J. P.: 1967. The structure of thiothixene, Chem. Commun. 1967: 743–744.
Scheel-Kruger, J.: 1972. Behavioural and biochemical comparison of amphetamine derivatives, cocaine, benztropine and tricyclic antidepressant drugs, Eur. J. Pharmacol. 18: 63–73.
Schmiedeberg, O., Koppe, R.: 1869. Das Muscarine, das Giftige Alkaloid des Fliegenpilzes, Vogel, Leipzig.
Schueler, F. W.: 1953. The statistical nature of the intramolecular distance factor of the muscarinic moiety, Arch. Int. Pharmacodyn. 93: 417–426.
Schueler, F. W., Hanna, C.: 1951. The pharmacological activities of some hydrazonium analogs related to acetylcholine tetramethylammonium and tetraethylammonium, Arch. Int. Pharmacodyn. 88: 351–360.
Schueler, F. W., Keasling, H. H.: 1951. Further studies on the RC (reversed carboxyl) analog of acetylcholine and some additional derivatives, J. Pharmacol. Exp. Ther. 103: 222–235.
Scott, K. A., Mautner, H. G.: 1967. Sulfur and selenium isologs related to acetylcholine and choline-IX, Biochem. Pharmacol. 16: 1903–1918.
Shader, R. I., Dimascio, A.: 1970. Psychotropic Drug Side Effects, Williams and Wilkins, Baltimore.
Shefter, E., Triggle, D. T.: 1970. Is there a unique conformation of cholinergic ligands responsible for muscarinic activity? Nature 227: 1354–1355.
Sheppard, H., Burghardt, C., Greengard, P.: 1973. The interaction of dopamine and its derivatives with the dopamine-sensitive adenylate cyclase of rat caudate nucleus, Pharmacologist 15: 231.
Simonart, A.: 1932, On the action of certain derivatives of choline, J. Pharmacol. Exp. Ther. 46: 157–193.
Simonart, A.: 1934. Contribution a l’etude des? alkyl cholines, Arch. Int. Pharmacodyn. 48: 328–332.
Simpson, T. R. Jr., Craig, J. C., Kumler, W. D.: 1967. Determination of the conformation of nicotine and some related compounds by nuclear magnetic resonance and dipole moments, J. Pharm. Sci. 56: 708–713.
Singhgrewal, R.: 1952. The pharmacological actions of 6-methyladrenaline, Brit. J. Pharmacol. 7: 338–348.
Snyder, S. H.: 1972. Catecholamines in the brain as mediators of amphetamine psychosis, Arch. Gen. Psychiat. 27: 169–179.
Snyder, S. H., Greenberg, D., Yamamura, H. I.: 1974. Antischizophrenicdrugsandbrain cholinergic receptors: Affinity for muscarinic sites predicts extrapyramidal effects, Arch. Gen. Psychiat., 31: 58–61.
Soudijn, W., van Wijngaarden, I.: 1972. Localization of 3H-pimozide in the rat brain in relation to its anti-amphetamine potency, J. Pharm. Pharmacol. 24: 773–780.
Stehle, R. L., Melville, K. I., Oldham, F. K.: 1936. Choline as a factor in the elaboration of adrenaline, J. Pharmacol. Exp. Ther. 56: 473–481.
Stenlake, J. B.: 1963. Some chemical aspects of neuromuscular block, in: Progress in Medicinal Chemistry, Vol. 3 ( G. P. Ellis, G. B. West, eds.), pp. 1–51, Butterworth, London.
Stoll, H. C.: 1948. Pharmacodynamic considerations of atropine and related compounds, Am. J. Med. Sci. 215: 577–592.
Swanson, E. E., Chen, K. K.: 1946. Comparison of pressor action of aliphatic amines, J. Pharmacol. Exp. Ther. 88: 10–13.
Swanson, E. E., Steldt, F. A., Chen, K. K.: 1945. Further observations on the pressor action of optical isomers of sympathomimetic amines, J. Pharmacol. Exp. Ther. 85: 70–73.
Taylor, D. B., Nederguard, O. A.: 1965. Relation between structure and action of quaternary ammonium neuromuscular blocking agents, Physiol. Rev. 45: 523–554.
Testa, B., Jenner, P.: 1973. Circular dichroic determination of the preferred conformation of nicotine and related chiral alkaloids in aqueous solution, Mol. Pharmacol. 9: 10–16.
Trendelenburg, U.: 1956. The action of 5-hydroxytryptamine on the nictitating membrane and on the superior cervical ganglion of the cat, Brit. J. Pharmacol. 11: 74–80.
Trendelenburg, U.: 1957. The action of morphine on the superior cervical ganglion and on the nictitating membrane of the cat, Brit. J. Pharmacol. 12: 79–85.
Trendelenburg, U., Muskus, A., Fleming, W. W., Alonso, S. B. G.: 1962. Modification by reserpine of the action of sympathomimetic amines in spinal cats; a classification of sympathomimetic amines, J. Pharmacol. Exp. Ther. 138: 170–180.
Triggle, D. J.: 1970. Adrenergic hormones and drugs, in: Medicinal Chemistry, Vol. II ( A. Burger, ed.), pp. 1235–1295, Wiley-Interscience, New York.
Triggle, D. J.: 1971. Neurotransmitter-Receptor Interactions, Academic Press, London.
Triggle, D. J.: 1972. Adrenergic receptors, Ann. Rev. Pharmacol. 12: 185–196.
Turtle, J. R., Kipnis, D. M.: 1967. An adrenergic receptor mechanism for the control of cyclic 3’,5’-adenosine monophosphate systems in tissue, Biochem. Biophys. Res. Commun. 28: 797–802.
Ungerstedt, U.: 1971. Stereotaxic mapping of the monoamine pathways in the rat brain, Acta Physiol. Scand. Suppl. 376: 1–48.
Urech, E., Marxer, A., Miescher, K.: 1950. Aminoalkyl-imidazoline, Helv. Chim. Acta 33: 1386–1407.
Vane, J. R.: 1957. A sensitive method for the assay of 5-hydroxytryptamine, Brit. J. Pharmacol. 12: 344–349.
Vane, J. R.: 1959. The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation, Brit. J. Pharmacol. 14: 87–98.
van Rossum, J. M.: 1962. Pharmacodynamics of parasympathetic drugs: Mechanism of action and structure action of tertiary ammonium salts, Arch. Int. Pharmacodyn. 140: 592–605.
van Rossum, J. M., Ariens, E. J.: 1959. Pharmacodynamics of parasympathetic drugs: Structure-action relations in homologous series of quaternary ammonium salts, Arch. Int. Pharmacodyn. 118: 418–446.
Waser, P. G.: 1961. Chemistry and pharmacology of muscarine, muscarone and some related compounds, Pharmacol. Rev. 13: 465–515.
Weissman, A., Koe, K. B., Tenen, S. S.: 1966. Antiamphetamine effects following inhibition of tyrosine hydroxylase, J. Pharmacol. Exp. Ther. 151: 339–352.
Welch, A. D., Roepke, M. H.: 1935. A comparative study of choline and certain of its analogues, J. Pharmacol. Exp. Ther. 55: 118–126.
Welsh, J. H., Taub, R.: 1951. The significance of the carbonyl group and ether oxygen in the reaction of Ach with receptor substance, J. Pharmacol. Exp. Ther. 103: 62–73.
Werner, L. H., Barrett, W. E.: 1967. In: Antihypertensive Agents (E. Schlittler, ed.), pp. 331–392, Academic Press, New York.
Whittaker, V. P.: 1963. In: Handbook of Experimental Pharmacology, Vol. 15 (G. B. Koelle, ed.), pp. 1–39, Springer, Berlin.
Wilkinson, S.: 1961. The history and chemistry of muscarine, Quart. Rev. Chem. Soc. 15: 153–171.
Woodruff, G. N.: 1971. Dopamine Receptors: A review, Comp. Gen. Pharmacol. 2: 439–455.
Woodruff, G. N., Walker, R. J.: 1969. The effect of dopamine and other compounds on the activity of neurones of Helix aspersa: Structure-activity relationships, Int. J. Neuropharmacol. 8: 279–289.
Woolley, D. W.: 1959. Highly potent antimetabolites of serotonin with litde serotonin-like action, Biochem. Pharmacol. 1: 51–59.
Woolley, D. W., Campbell, N. K.: 1962. Serotonin-like and antiserotonin properties of psilocybin and psilocin, Science 136: 777–779.
Wurzel, M.: 1959. A suggested mechanism for the action of choline esters on animal organs, inferred from a study of the effects of choline, J-methylcholine and thiocholine-esters, Experientia 15: 430–433.
Yamamoto, C.: 1967. Pharmacologic studies of norepinephrine, acetylcholine and related compounds on neurons in Deiters’ nucleus and the cerebellum, J. Pharmacol. Exp. Ther. 156: 39–47.
Yamamura, H. I., Snyder, S. H.: 1974. Muscarinic cholinergic receptor binding in rat brain, Prox. Natl. Acad. Sci., 71: 1725–1729.
Yeh, B. K., Mcnay, J. L., Goldberg, L. I.: 1969. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: Evidence of a specific dopamine receptor, J. Pharmacol. Exp. Ther. 168: 303–309.
Zirkle, C. L., Kaiser, C.: 1970. Antipsychotic agents, in: Medicinal Chemistry, Vol. 11 (A. Burger, ed.), pp. 1410–1469, Wiley-InterScience, New York.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1975 Plenum Press, New York
About this chapter
Cite this chapter
Horn, A.S. (1975). Structure-Activity Relations for Neurotransmitter Receptor Agonists and Antagonists. In: Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds) Principles of Receptor Research. Handbook of Psychopharmacology, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-3168-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-4684-3168-1_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-3170-4
Online ISBN: 978-1-4684-3168-1
eBook Packages: Springer Book Archive